Dr Offin and Dr Schoenfeld on New Lung Cancer Advances

In this episode of The OncoloGIST, Michael Offin, MD, and Adam Schoenfeld, MD, thoracic medical oncologists at Memorial Sloan Kettering Cancer Center, highlight key updates and emerging trends from the 2026 European Lung Cancer Congress (ELCC). While noting a limited amount of new literature specifically for certain patient populations, the experts identify several "standout" presentations that are shaping the future of thoracic oncology.

A primary focus of the conversation is the updated data from the FLAURA2 trial. Dr Offin emphasizes the sustained benefit observed with the combination of osimertinib (Tagrisso) and chemotherapy for patients with EGFR-mutated lung cancer. The oncologists are particularly focused on how these results will influence first-line treatment strategies, while they continue to wait for more definitive overall survival data.

The discussion also explores 2 major avenues for research and clinical opportunity:

• Targeted Therapies for Mesothelioma: Traditionally viewed as a disease with few genetic targets, mesothelioma is now being re-evaluated through deeper genomic sequencing and protein expression analysis. Researchers are actively working to identify potential targets, leading to both new clinical trials and the potential to repurpose existing drugs.
• Next-Generation Immunotherapy: The speakers discuss the evolving role of immunotherapy beyond PD-1/PD-L1 inhibitors. They highlight the importance of investigating different modalities, such as cellular therapies, bispecific antibodies, and vaccine-based approaches, to overcome current limitations in treatment response.